Welcome to our dedicated page for Cannapharmarx news (Ticker: CPMD), a resource for investors and traders seeking the latest updates and insights on Cannapharmarx stock.
CannapharmaRx, Inc. (CPMD) provides investors and industry observers with comprehensive access to official company announcements and market developments. This centralized resource aggregates press releases, financial disclosures, and operational updates from the Canadian cannabis producer.
Visitors will find timely information on cultivation innovations, international distribution partnerships, and regulatory milestones. Key updates include production facility expansions, strategic alliances with global distributors, and advancements in cultivation efficiency through proprietary technologies.
The page serves as a reliable source for tracking CPMD's progress in medical cannabis markets and low-cost production initiatives. Content spans earnings reports, leadership updates, and quality assurance developments across domestic and international operations.
Bookmark this page for direct access to CannapharmaRx's verified communications, including material updates about its Alberta grow facilities and partnerships in Israel/Latin America. Check regularly for new developments in cannabis production and global market expansion.
CannaPharmaRx (OTC PINK:CPMD) has signed a Memorandum of Understanding (MOU) with Nasha Genetics to enhance its presence in the medical cannabis sector. Nasha, recognized for its cannabis strain genetics, will supply CPMD with genetics that can produce high-quality cannabis with at least 20% THC. Under the agreement, Nasha will manage costs related to the genetic supply, while CannaPharmaRx will handle cultivation within 10 days of receiving the genetics. The partnership allows for a 7.5-year term during which Nasha will order at least 400 KG of cannabis from CannaPharmaRx, which will seek necessary export licenses for markets beyond Israel. A definitive agreement is expected within 45 days.
CannaPharmaRx (CPMD) announced a 24-month Supply Agreement with Israeli firm Y.S.A Holdings. Under this deal, CannaPharmaRx will cultivate cannabis in Canada and supply a minimum of 400kg annually to YSA for sales in Israel and Morocco, with potential revenues ranging from $6 million to $15 million per year. Deliveries are expected to start in Q3, with purchase orders occurring up to four times a year. This agreement is part of CannaPharmaRx's strategy to build an international brand featuring up to 15 cannabis strains from its exclusive inventory.
CannaPharmaRx (OTC PINK:CPMD) has signed a letter of intent to acquire LTB Management LLC, an e-commerce platform that enhances online sales. The deal is expected to close in February 2023. LTB's revenues were approximately $3 million in 2022 and are projected to exceed $5 million in 2023 as new products, including cannabis, are introduced. This acquisition is aimed at boosting CannaPharmaRx's sales in Israel and Europe and will diversify its revenue streams, targeting an annual cannabis sales run rate of nearly $30 million. The platform will also enable additional payment options including e-wallets and cryptocurrencies.
FAQ
What is the current stock price of Cannapharmarx (CPMD)?
What is the market cap of Cannapharmarx (CPMD)?
